Lupus hopes dashed for ustekinumab after Phase 3 trial discontinued

The high expectations for the anti-IL 12/23 antibody ustekinumab (Stelara) in SLE based on Phase 2 trial results have not been borne out in larger Phase 3 studies. Manufacturer Janssen has announced it is discontinuing the Phase 3 LOTUS study of ustekinumab in SLE due to lack of efficacy seen in preliminary results. LOTUS was ...

Already a member?

Login to keep reading.

© 2021 the limbic